Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo’s Generics Add $30m Due To COVID-19 Impact

Company Sees $75m Overall Growth In Q1 From Coronavirus Demand

Executive Summary

Despite reporting 14% growth in the first quarter of 2020, Endo has forecast a downturn in the second quarter and has withdrawn its full-year financial guidance due to uncertainty regarding the continued impact of the coronavirus pandemic.

You may also be interested in...



AAM Urges US Senate To Back Domestic Production

While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”

WHO Launches COVID-19 Technology Access Pool

C-TAP, the voluntary initiative aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all, has been launched by the WHO, in partnership with Costa Rica.

Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

Topics

Related Companies

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel